The final of three roundtables on treating Chronic Limb-threatening Ischemia (CLTI) will cover the Global Limb Anatomic Staging System—GLASS.
The virtual roundtable, on GLASS staging and treatment outcomes, will be held from 6 to 7:30 p.m. CDT Monday, Oct. 10. Register at vascular.org/CLTIRoundtable3. “Revascularization” is part of “Translating Guidelines into Practice: Global Vascular Guideline (GVG) on the Management of Patients with CLTI.”
Michael Conte, MD, a lead GVG editor, will moderate this session. Speakers will include Leigh Ann O’Banion, MD, Patrick Geraghty, MD, Marc Schermerhorn, MD, and Peter A. Schneider, MD.
Participants should download the SVS Interactive Practice Guidelines (iPG) app from either the (Apple) App or Google Play stores.
GLASS involves defining a preferred target artery path, and then estimating limb-based patency, with three resultant stages of complexity for intervention. GLASS was proposed as part of the development of the Global Vascular Guidelines for patients with CLTI.
“We will be focusing on every-day clinical decision-making around revascularization options,” said Conte, including delving into assessing the anatomic complexity of disease and use of GLASS scheme and calculator in addition to surgical candidacy overall. The session will help expand physicians’ knowledge base and improve clinical confidence and effectiveness in treating CLTI patients.
It will cover GLASS plus its current limitations and the growing impact of pedal artery disease in clinical practice. Finally, panelists will address the latest data on the risks and benefits of drug elution in the CLTI population.
Throughout the roundtables, speakers have used a single sample patient to design treatment strategies and demonstrate how to apply the recommendations from the GVG into practice.
Conte will first provide an introduction and overview for the focus of this session. Other topics and speakers include:
A short survey will be conducted before and after the session, and follow-up survey will follow 60 days later to gauge and evaluate if guidelines were easy to translate into daily clinical practice. Participants will receive the clinical practice guidelines, implementation tools consisting of guideline pocket guides, and link to the app to ensure practicality in aiding participants in improving their clinical practice.
Conte pointed out these three webinars are important to present now, with trial results on treating CLTI patients due to be published in the coming months. The BEST-CLI trial is investigating open and endovascular options while BASIL 2 and 3 (Balloon versus stenting in severe ischemia of the leg) looks into the use of different kinds of stenting, including plain balloon angioplasty and the use of drug-coated balloons and drug-eluting stents.
Learn more about the roundtable and register at vascular.org/CLTIRoundtable3.
